Riverview Acquisition Corp. (RVAC) Shareholders Approve Westrock Coffee Deal
by Marlena Haddad on 2022-08-25 at 5:01pm

Riverview Acquisition Corp. (NASDAQ:RVAC) announced this afternoon that its shareholders approved its combination with coffee and tea supplier Westrock Coffee at a special meeting earlier today.

At the special meeting, a total of 24,469,389 shares, or 78.3% of RVAC’s issued and outstanding shares of common stock were present. Holders of 23,428,049 shares of common stock, or 75.0% of the outstanding common stock of RVAC, voted in favor of the business combination.

The SPAC divulged in an 8-K yesterday that about 73.5% of its shares were redeemed in connection with its vote, marking August’s best redemption result thus far.

Riverview also disclosed yesterday that it will now be left with approximately $66 million in its trust account. Following the redemptions and prior to payment of transaction expenses, Westrock expects to receive approximately $295.9 million in gross proceeds, which includes $201.4 million in expected proceeds from the issuance of equity in the Riverview PIPE Financing, $66.0 million from the distribution of Riverview’s trust account and $28.5 million from the concurrent sale of an aggregate of 2,850,000 Westrock Common Shares, at a purchase price of $10.00 per share.

The parties expect the business combination to close tomorrow, August 26, and the combined company’s common stock is expected to begin trading on Nasdaq on Monday, August 29, under the new ticker symbol, “WEST”.

Riverview initially announced the $1.1 billion combination with Westrock Coffee on April 4. Little Rock, Arkansas-based Westrock Coffee supplies innovative coffee, tea, flavors, extracts, and ingredients products to retail, food service and restaurant, convenience store, and hospitality industries around the world.

Scott Ford, CEO and Co-Founder of Westrock Coffee recently joined SPACInsider’s podcast to discuss the deal in greater detail.


ADVISORS

  • Stifel is serving as Lead Financial Advisor and Wells Fargo Securities, LLC is serving as Financial Advisor to Westrock Coffee.
  • Stifel and Wells Fargo Securities, LLC are both serving as Capital Market Advisors to Westrock Coffee.
  • Wachtell, Lipton, Rosen & Katz is acting as legal counsel to Westrock Coffee.
  • Stephens Inc. is serving as Financial and Capital Markets Advisor
  • Cantor Fitzgerald & Co. is serving as Capital Markets Advisor to Riverview.
  • King & Spalding LLP is acting as legal counsel to Riverview
Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved